COMy 2021 | Dara-Kd shows efficacy in len-refractory cohort in latest CANDOR reports
Saad Usmani, MD, University of North Carolina School of Medicine, Chapel Hill, NC, provides an update on the Phase III CANDOR trial (NCT03158688) comparing the efficacy of daratumumab (dara) plus carfilzomib and daratumumab (Kd) to Kd alone in patients with relapsed/refractory multiple myeloma. Initial progression-free survival (PFS) data were reported at ASH 2019 with a median follow-up of 17 months. At this time point, median PFS was 15.2 months in the Kd arm and not reached in the dara-Kd arm. With an additional 11 months follow up, a median PFS of 28.6 months was reached in the daratumumab cohort. Subgroup analyses demonstrated that the observed survival benefit with daratumumab use was consistent in patients with prior lenalidomide exposure/refractoriness as compared to the overall population. Additionally, assessments of measurable residual disease (MRD) showed that, to date, no patients reaching an MRD-negative complete response have progressed. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Research funding: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Consulting fees: Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda
Speaking fees: Celgene, Janssen, Sanofi, Takeda.
